Market Place
Sourcing Support
All News #Library
Rare Diseases
BridgeBio Submit NDA for BBP-418 for People Living with LGMD2I/R9
30 Mar 2026 //
GLOBENEWSWIRE
Bridgebio`s Muscle Weakness Data Impress Ahead Of FDA Filing
13 Mar 2026 //
PRESS RELEASE
BBP-418 Shows Efficacy in Ph3 FORTIFY Study in LGMD2I/R9
11 Mar 2026 //
GLOBENEWSWIRE
Bridgebio Pops On Late-Stage Limb-Girdle Muscular Dystrophy Data
27 Oct 2025 //
BIOSPACE
Unnatural Products Announces BridgeBio Option for Macrocyclic
03 Dec 2024 //
GLOBENEWSWIRE
BridgeBio Selects PANTHERx® for Attruby™ Distribution
26 Nov 2024 //
PR NEWSWIRE
US FDA approves BridgeBio`s drug for rare heart condition
23 Nov 2024 //
PRESS RELEASE
BridgeBio Receives FDA Designation For BBP-418 In LGMD2I/R9
18 Jun 2024 //
GLOBENEWSWIRE
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’
12 Jul 2023 //
GLOBENEWSWIRE
Rare disease player BridgeBio draws buyout interest
28 Mar 2023 //
FIERCE PHARMA
BridgeBio company sells off rare disease candidate to Galderma partner
28 Jan 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.